Safety of hormonal steroid contraceptive use for hepatitis B virus carrier women
Wang, P.; Lai, Z.; Tang, J.; Xu, W.; Mi, X.; Ma, F.
Pharmacoepidemiology and Drug Safety 9(3): 245-246
2000
ISSN/ISBN: 1099-1557 PMID: 19025826 DOI: 10.1002/1099-1557(200005/06)9:3<245::aid-pds500>3.0.co;2-7Document Number: 261913
To investigate the relationship between hormonal steroid contraception and liver function in HBsAg positive women, 159 HBsAg positive women with normal liver function and negative anti-HBc-IgM are collected for a non-randomized comparative trial, 78 in low dose combined OC group and 81 in control group. Follow up observations will be at three and six months after admission. During the observation, no significant differences between two groups are found including serum GPT, albumin, serum bilirubin and prothrombin time. However in the OC group, there is one case who has had a transient moderate abnormal SGPT. No any hepatitis manifestations are found in both groups. The current primary study supports the safety of low dose OCs in HBsAg positive women. However, additional investigations in larger sample are needed. Copyright (c) 2000 John Wiley & Sons, Ltd.